TransDigm Group Incorporated
$90.84B- Market cap
- $64.23B
- Debt
- +$29.42B
- Cash
- −$2.81B
Capital structure 69% equity / 31% debt · EV / Revenue 10.29x · EV / EBITDA 20.30x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: TDG stock price vs VNDA: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at VNDA's multiple
Needs VNDA P/E.
Implied fair value · at TDG's multiple
Needs EPS (TTM) is negative, TDG P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: TDG FY 2025 (ended Sep 30, 2025) · VNDA FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 69% equity / 31% debt · EV / Revenue 10.29x · EV / EBITDA 20.30x
Capital structure 81% equity / 19% debt · EV / Revenue 1.49x
TDG carries the larger enterprise value at $90.84B against $321.69M; VNDA trades on the lower EV / Revenue multiple (1.49x vs 10.29x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
TransDigm Group Incorporated · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
VANDA PHARMACEUTICALS INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
-3.04x
0.24x
Net debt / EBITDA
Leverage against operating earnings
5.95x
0.05x
Cash and equivalents
Liquid reserves on the balance sheet
$2.81B
$84.85M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
BOEING CO
TDG vs BA
LOCKHEED MARTIN CORP
TDG vs LMT
NORTHROP GRUMMAN CORP /DE/
TDG vs NOC
AAR CORP
TDG vs AIR
Howmet Aerospace Inc.
TDG vs HWM
SUPERNUS PHARMACEUTICALS, INC.
TDG vs SUPN
CATALYST PHARMACEUTICALS, INC.
TDG vs CPRX
Harmony Biosciences Holdings, Inc.
TDG vs HRMY
ELI LILLY & Co
TDG vs LLY
INCYTE CORP
TDG vs INCY
Sarepta Therapeutics, Inc.
TDG vs SRPT
$29.42B
$78.23M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.